Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UCMYM802
- Development stage
- Phase 1
- Lead developer
- UTC Therapeutics
- Modality
- Cell Therapies, Gene Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
UCMYM802 is an investigational cell therapy consisting of T lymphocytes genetically modified to express a chimeric antigen receptor (CAR) targeting the human tumor-associated antigen mesothelin. The product uses circular mRNA technology to encode the anti-mesothelin CAR, enabling targeted recognition and destruction of mesothelin-positive malignant solid tumor cells. It is being developed by UTC Therapeutics (Shanghai) for the treatment of advanced solid tumors expressing mesothelin, with its first-in-human Phase 1 clinical trial initiated in March 2024[1][2][3][5]. The primary aim is to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy in patients with advanced mesothelin-positive malignancies.
- Other names
- anti-mesothelin CAR T cells UCMYM802
02
Targets
Mesothelin
Beyond the preview
Go deeper on UCMYM802.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UCMYM802.